{
    "organizations": [],
    "uuid": "c7183c070783aeff0ac3aa7d23b5698c0c2d1209",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-syros-announces-2018-strategic-pri/brief-syros-announces-2018-strategic-priorities-and-expected-milestones-idUSFWN1P30PM",
    "ord_in_thread": 0,
    "title": "BRIEF-Syros Announces 2018 Strategic Priorities And Expected Milestones",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Syros Pharmaceuticals Inc:\n* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES\n* ON TRACK TO REPORT CLINICAL DATA ON SY-1425 COMBINATIONS AND SY-1365\n* CO HAD ABOUT $81.9 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPT 30, 2017\n* EXPECTS TO BE ABLE TO FUND ANTICIPATED OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:18:00.000+02:00",
    "crawled": "2018-01-09T17:20:21.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "syros",
        "pharmaceutical",
        "inc",
        "syros",
        "announces",
        "strategic",
        "priority",
        "expected",
        "milestone",
        "track",
        "report",
        "clinical",
        "data",
        "combination",
        "co",
        "million",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "sept",
        "expects",
        "able",
        "fund",
        "anticipated",
        "operating",
        "expense",
        "capital",
        "expenditure",
        "requirement",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}